Please assess the completion status of the following clinical trial:

Trial Title: Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Able to provide informed consent~* Able to comply with study procedures~* History of enteric or idiopathic hyperoxaluria and at least one calcium oxalate kidney stone~* Hyperoxaluria \>36mg of oxalate/24-hr~* May be taking drugs for the prevention of stone disease as long as there have been no changes in these medications for at least 3 months~Exclusion Criteria:~* Uric acid ≥1.5g/24-hr~* Estimated glomerular filtration rate of \< 60 mL/min~* Positive results from drug urine screen~* Requires daily vitamin C (defined as \>10 days of \>300 mg/day)~* Diagnosis of hypercalcemia or hypothyroidism~* Obstructive uropathy, chronic urosepsis, renal failure, renal tubular acidosis, primary hyperparathyroidism, primary hyperoxaluria, pure uric acid and cystine stones, and/or medullary sponge kidney.~* Auto-immune disorder requiring high dose steroids or other immunosuppressant drugs.~* Subjects who are pregnant. Women of childbearing potential must have a negative pregnancy test prior to enrollment and must practice approved methods of birth control during the trial~* History of cancer diagnosis except for within the past 5 years excluding dermal squamous and/or basal cell carcinoma or cervical carcinoma in situ.~* Taken investigational compound within 30 days prior to the first day of the study~* Treatment with cholestyramine~* Average daily dietary intake of \<75 mg oxalate per day calculated from diet recalls

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ALLN-177 (Type: EXPERIMENTAL): Recurrent Calcium Oxalate Stone Formers with Hyperoxaluria Subjects with Enteric or Idiopathic hyperoxaluria~Dosing: 5 capsules of ALLN-177 orally (p.o.) up to 3 times daily (TID) with meals for 4 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).